These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 19808684)

  • 21. Grafting of "abbreviated" complementarity-determining regions containing specificity-determining residues essential for ligand contact to engineer a less immunogenic humanized monoclonal antibody.
    De Pascalis R; Iwahashi M; Tamura M; Padlan EA; Gonzales NR; Santos AD; Giuliano M; Schuck P; Schlom J; Kashmiri SV
    J Immunol; 2002 Sep; 169(6):3076-84. PubMed ID: 12218124
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Single-Framework Synthetic Antibody Library Containing a Combination of Canonical and Variable Complementarity-Determining Regions.
    Maruthachalam BV; El-Sayed A; Liu J; Sutherland AR; Hill W; Alam MK; Pastushok L; Fonge H; Barreto K; Geyer CR
    Chembiochem; 2017 Nov; 18(22):2247-2259. PubMed ID: 28884521
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Investigation of anomalous charge variant profile reveals discrete pH-dependent conformations and conformation-dependent charge states within the CDR3 loop of a therapeutic mAb.
    Lan W; Valente JJ; Ilott A; Chennamsetty N; Liu Z; Rizzo JM; Yamniuk AP; Qiu D; Shackman HM; Bolgar MS
    MAbs; 2020; 12(1):1763138. PubMed ID: 32432964
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aggregation-resistant domain antibodies engineered with charged mutations near the edges of the complementarity-determining regions.
    Perchiacca JM; Ladiwala AR; Bhattacharya M; Tessier PM
    Protein Eng Des Sel; 2012 Oct; 25(10):591-601. PubMed ID: 22843678
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An antibody-based biomarker discovery method by mass spectrometry sequencing of complementarity determining regions.
    Dekker LJ; Zeneyedpour L; Brouwer E; van Duijn MM; Sillevis Smitt PA; Luider TM
    Anal Bioanal Chem; 2011 Jan; 399(3):1081-91. PubMed ID: 21107826
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Designing antibodies for the inhibition of gastrin activity in tumoral cell lines.
    Barderas R; Shochat S; Timmerman P; Hollestelle MJ; Martínez-Torrecuadrada JL; Höppener JW; Altschuh D; Meloen R; Casal JI
    Int J Cancer; 2008 May; 122(10):2351-9. PubMed ID: 18224686
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Defining the complementarities between antibodies and haptens to refine our understanding and aid the prediction of a successful binding interaction.
    Al Qaraghuli MM; Palliyil S; Broadbent G; Cullen DC; Charlton KA; Porter AJ
    BMC Biotechnol; 2015 Oct; 15():99. PubMed ID: 26498921
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues.
    Wu H; Nie Y; Huse WD; Watkins JD
    J Mol Biol; 1999 Nov; 294(1):151-62. PubMed ID: 10556035
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Construction of a large synthetic human scFv library with six diversified CDRs and high functional diversity.
    Yang HY; Kang KJ; Chung JE; Shim H
    Mol Cells; 2009 Feb; 27(2):225-35. PubMed ID: 19277506
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Deep Sequencing-guided Design of a High Affinity Dual Specificity Antibody to Target Two Angiogenic Factors in Neovascular Age-related Macular Degeneration.
    Koenig P; Lee CV; Sanowar S; Wu P; Stinson J; Harris SF; Fuh G
    J Biol Chem; 2015 Sep; 290(36):21773-86. PubMed ID: 26088137
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The long third complementarity-determining region of the heavy chain is important in the activity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5.
    Zwick MB; Komori HK; Stanfield RL; Church S; Wang M; Parren PW; Kunert R; Katinger H; Wilson IA; Burton DR
    J Virol; 2004 Mar; 78(6):3155-61. PubMed ID: 14990736
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-tumor activities of peptides corresponding to conserved complementary determining regions from different immunoglobulins.
    Figueiredo CR; Matsuo AL; Massaoka MH; Polonelli L; Travassos LR
    Peptides; 2014 Sep; 59():14-9. PubMed ID: 24972300
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antibody Mimetics, Peptides, and Peptidomimetics.
    Zhang X; Diraviyam T
    Methods Mol Biol; 2017; 1575():3-13. PubMed ID: 28255871
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Novel Human scFv Library with Non-Combinatorial Synthetic CDR Diversity.
    Bai X; Kim J; Kang S; Kim W; Shim H
    PLoS One; 2015; 10(10):e0141045. PubMed ID: 26484868
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antibody complementarity-determining regions (CDRs) can display differential antimicrobial, antiviral and antitumor activities.
    Polonelli L; Pontón J; Elguezabal N; Moragues MD; Casoli C; Pilotti E; Ronzi P; Dobroff AS; Rodrigues EG; Juliano MA; Maffei DL; Magliani W; Conti S; Travassos LR
    PLoS One; 2008 Jun; 3(6):e2371. PubMed ID: 18545659
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro affinity maturation of an anti-PSA antibody for prostate cancer diagnostic assay.
    Muller BH; Savatier A; L'Hostis G; Costa N; Bossus M; Michel S; Ott C; Becquart L; Ruffion A; Stura EA; Ducancel F
    J Mol Biol; 2011 Dec; 414(4):545-62. PubMed ID: 22019475
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Disabling erbB receptors with rationally designed exocyclic mimetics of antibodies: structure-function analysis.
    Berezov A; Zhang HT; Greene MI; Murali R
    J Med Chem; 2001 Aug; 44(16):2565-74. PubMed ID: 11472210
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Affinity maturation of antibodies by combinatorial codon mutagenesis versus error-prone PCR.
    Simons JF; Lim YW; Carter KP; Wagner EK; Wayham N; Adler AS; Johnson DS
    MAbs; 2020; 12(1):1803646. PubMed ID: 32744131
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Affinity maturation of a novel antagonistic human monoclonal antibody with a long VH CDR3 targeting the Class A GPCR formyl-peptide receptor 1.
    Douthwaite JA; Sridharan S; Huntington C; Hammersley J; Marwood R; Hakulinen JK; Ek M; Sjögren T; Rider D; Privezentzev C; Seaman JC; Cariuk P; Knights V; Young J; Wilkinson T; Sleeman M; Finch DK; Lowe DC; Vaughan TJ
    MAbs; 2015; 7(1):152-66. PubMed ID: 25484051
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Humanization of Chicken-Derived scFv Using Yeast Surface Display and NGS Data Mining.
    Elter A; Bogen JP; Hinz SC; Fiebig D; Macarrón Palacios A; Grzeschik J; Hock B; Kolmar H
    Biotechnol J; 2021 Mar; 16(3):e2000231. PubMed ID: 33078896
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.